Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
NCT06031558
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
120
Enrollment
OTHER
Sponsor class
Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG:
SY-5007
Sponsor
Shouyao Holdings (Beijing) Co. LTD